In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Immunic Inc (NASDAQ: IMUX) closed at $0.64 down -1.71% from its previous closing price of $0.65. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 1.25 million shares were traded. IMUX stock price reached its highest trading level at $0.6849 during the session, while it also had its lowest trading level at $0.6256.
Ratios:
For a deeper understanding of Immunic Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Roth Capital on November 07, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
On September 29, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 13 ’25 when Nash Duane bought 20,000 shares for $0.83 per share. The transaction valued at 16,694 led to the insider holds 36,032 shares of the business.
Tardio Jason bought 12,512 shares of IMUX for $9,884 on Jun 05 ’25. The President and COO now owns 12,512 shares after completing the transaction at $0.79 per share. On Jun 04 ’25, another insider, Vitt Daniel, who serves as the CEO and Director of the company, bought 15,000 shares for $0.77 each. As a result, the insider paid 11,550 and bolstered with 29,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMUX now has a Market Capitalization of 76849904 and an Enterprise Value of 42509912.
Stock Price History:
The Beta on a monthly basis for IMUX is 1.58, which has changed by -0.31794333 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, IMUX has reached a high of $1.39, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is -3.08%, while the 200-Day Moving Average is calculated to be -23.36%.
Shares Statistics:
For the past three months, IMUX has traded an average of 1.42M shares per day and 1682780 over the past ten days. A total of 120.28M shares are outstanding, with a floating share count of 118.71M. Insiders hold about 1.31% of the company’s shares, while institutions hold 52.21% stake in the company. Shares short for IMUX as of 1767139200 were 6573373 with a Short Ratio of 4.64, compared to 1764288000 on 5587275. Therefore, it implies a Short% of Shares Outstanding of 6573373 and a Short% of Float of 5.55.
Earnings Estimates
The stock of Immunic Inc (IMUX) is currently drawing attention from 9.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.07 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.55 and -$0.76 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.37, with 9.0 analysts recommending between -$0.05 and -$0.67.
